Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

Leoni RolfesMarc PawlitzkiSteffen PfeufferChristopher NelkeAnke LuxRefik PulChristoph KleinschnitzKonstanze KleinschnitzRebeca RogallKatrin PapeStefan BittnerFrauke ZippClemens WarnkeYasemin GoereciMichael SchroeterJens IngwersenOrhan Aktas Luisa KlotzTobias RuckHeinz WiendlSven G Meuth

Published in: Neurology(R) neuroimmunology & neuroinflammation (2021)

This study provides Class IV evidence that for patients with RRMS, an EID of at least 4 weeks does not diminish effectiveness of ocrelizumab.

Keyphrases

multiple sclerosis
coronavirus disease
sars cov
randomized controlled trial
systematic review
white matter
respiratory syndrome coronavirus